Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Journal

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PPO.0000000000000309PMID 29601331PMCID PMC5880324
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer

  2018cited by this paper
• Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients

  2017cited by this paper
• Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

  2017cited by this paper
• Technical Advances to Study Extracellular Vesicles

  2017cited by this paper
• Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests

  2017cited by this paper
• Extracellular vesicles compartment in liquid biopsies: Clinical application.

  2017cited by this paper
• Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer

  2017cited by this paper
• Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples.

  2017cited by this paper
• Detection of Circulating Tumor DNA in the Blood of Cancer Patients: An Important Tool in Cancer Chemoprevention.

  2016cited by this paper
• High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

  2016cited by this paper
• Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

  2016cited by this paper
• Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

  2016cited by this paper
• Multiparameter Evaluation of the Heterogeneity of Circulating Tumor Cells Using Integrated RNA In Situ Hybridization and Immunocytochemical Analysis

  2016cited by this paper
• Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

  2015cited by this paper
• Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

  2015cited by this paper
• Frequent expression of PD‐L1 on circulating breast cancer cells

  2015cited by this paper
• Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer

  2015cited by this paper
• Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

  2015cited by this paper
• Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

  2015cited by this paper
• Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

  2014cited by this paper
• Molecular profiling of single circulating tumor cells with diagnostic intention

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014cited by this paper
• The dynamic range of circulating tumor DNA in metastatic breast cancer

  2014cited by this paper
• Challenges in circulating tumour cell research

  2014cited by this paper
• Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients

  2014cited by this paper
• Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

  2014cited by this paper
• Breaking a Vicious Cycle

  2013cited by this paper
• Analysis of circulating tumor DNA to monitor metastatic breast cancer.

  2013cited by this paper
• Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology.

  2013cited by this paper
• Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

  2013cited by this paper
• Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

  2012cited by this paper
• Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

  2012cited by this paper
• Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy

  2012cited by this paper
• Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis.

  2012cited by this paper
• Cell-free nucleic acids as biomarkers in cancer patients

  2011cited by this paper
• Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

  2011cited by this paper
• M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis

  2010cited by this paper
• MicroRNAs as biomarkers in rheumatic diseases

  2010cited by this paper
• Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results.

  2010cited by this paper
• Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

  2010cited by this paper
• Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

  2010cited by this paper
• Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

  2010cited by this paper
• Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells

  2009cited by this paper
• Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.

  2009cited by this paper
• Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases

  2008cited by this paper
• Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

  2008cited by this paper
• Circulating mutant DNA to assess tumor dynamics

  2008cited by this paper
• Cancer biomarker profiling with microRNAs

  2008cited by this paper
• HER-2 gene amplification can be acquired as breast cancer progresses.

  2004cited by this paper
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

  2004cited by this paper
• Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.

  2002cited by this paper
• Tailoring of hormonal therapy in prostate cancer

  2000cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper
• [Not Available].

  1948cited by this paper

• Liquid Biopsy for Medical Imaging Analysis in Cancer Diagnosis.

  2025cites this paper
• Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling

  2024cites this paper
• liquid biopsy holds a promising approach for the early detection of cancer: Current information and future perspectives.

  2024cites this paper
• Extrinsic and intrinsic preanalytical variables affecting liquid biopsy in cancer

  2023cites this paper
• The Role of the Innate Immune System in Cancer Dormancy and Relapse

  2021cites this paper
• The Advent of Circulating Tumor DNA in the Management of Ovarian Cancer

  2021cites this paper
• The usefulness of microRNA in urine and saliva as a biomarker of gastroenterological cancer

  2021cites this paper
• Triple-negative breast cancer: A run-through of features, classification and current therapies

  2021cites this paper
• Systemic Investigation Identifying Salivary miR-196b as a Promising Biomarker for Early Detection of Head-Neck Cancer and Oral Precancer Lesions

  2021cites this paper
• Triple-negative breast cancer: promising prognostic biomarkers currently in development

  2020cites this paper
• Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?

  2020cites this paper
• The emerging role of cell-free DNA as a molecular marker for cancer management

  2019cites this paper
• Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations

  2019cites this paper
• Extrinsic and intrinsic preanalytical variables affecting liquid Extrinsic and intrinsic preanalytical variables affecting liquid biopsy in cancer biopsy in cancer

  year unknowncites this paper